Bioventures 2018 L.P. Mpm Sells 192,500 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) major shareholder Bioventures 2018 L.P. Mpm sold 192,500 shares of the business’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $7.41, for a total transaction of $1,426,425.00. Following the completion of the sale, the insider owned 3,913,952 shares in the company, valued at $29,002,384.32. This represents a 4.69% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Bioventures 2018 L.P. Mpm also recently made the following trade(s):

• On Wednesday, September 9th, Bioventures 2018 L.P. Mpm sold 28,837 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.13, for a total value of $205,607.81.
• On Friday, September 4th, Bioventures 2018 L.P. Mpm sold 38,500 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.11, for a total transaction of $273,735.00.
• On Thursday, September 3rd, Bioventures 2018 L.P. Mpm sold 32,263 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.17, for a total transaction of $231,325.71.
• On Wednesday, September 2nd, Bioventures 2018 L.P. Mpm sold 25,131 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.19, for a total transaction of $180,691.89.
• On Tuesday, September 1st, Bioventures 2018 L.P. Mpm sold 29,088 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.06, for a total transaction of $205,361.28.
• On Monday, August 31st, Bioventures 2018 L.P. Mpm sold 44,259 shares of Entrada Therapeutics stock. The shares were sold at an average price of $6.99, for a total transaction of $309,370.41.
• On Friday, August 28th, Bioventures 2018 L.P. Mpm sold 3,733 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.01, for a total transaction of $26,168.33.
• On Thursday, August 27th, Bioventures 2018 L.P. Mpm sold 38,922 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.20, for a total transaction of $280,238.40.

Entrada Therapeutics Price Performance

Shares of Entrada Therapeutics stock opened at $6.42 on Friday. The firm has a fifty day moving average price of $7.02 and a 200 day moving average price of $9.06. Entrada Therapeutics, Inc. has a 1 year low of $5.02 and a 1 year high of $16.45. The stock has a market cap of $249.99 million, a PE ratio of -1.62 and a beta of -0.25.

Entrada Therapeutics (NASDAQ:TRDA) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.04). The business had revenue of $0.90 million during the quarter, compared to analysts’ expectations of $2.32 million. Entrada Therapeutics had a negative net margin of 3,537.73% and a negative return on equity of 57.61%. As a group, equities analysts expect that Entrada Therapeutics, Inc. will post -4.03 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. 5AM Venture Management LLC acquired a new position in Entrada Therapeutics in the 2nd quarter valued at about $29,854,949. BlackRock Inc. acquired a new stake in shares of Entrada Therapeutics during the 2nd quarter worth approximately $19,013,000. Millennium Management LLC increased its holdings in shares of Entrada Therapeutics by 391.2% during the 3rd quarter. Millennium Management LLC now owns 836,609 shares of the company’s stock worth $4,852,000 after buying an additional 666,287 shares during the last quarter. Nantahala Capital Management LLC purchased a new stake in shares of Entrada Therapeutics during the 2nd quarter valued at approximately $2,212,232. Finally, Citadel Advisors LLC raised its position in shares of Entrada Therapeutics by 234.5% during the 3rd quarter. Citadel Advisors LLC now owns 335,741 shares of the company’s stock valued at $1,947,000 after buying an additional 235,384 shares during the period. Institutional investors and hedge funds own 86.39% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Roth Capital reaffirmed a “buy” rating and set a $11.00 target price on shares of Entrada Therapeutics in a research note on Wednesday, August 12th. Wall Street Zen upgraded shares of Entrada Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 5th. Guggenheim decreased their price target on shares of Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating on the stock in a research note on Monday, June 8th. Finally, Weiss Ratings upgraded shares of Entrada Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, August 31st. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Entrada Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $17.75.

Entrada Therapeutics News Roundup

Here are the key news stories impacting Entrada Therapeutics this week:

• Neutral Sentiment: Entrada announced two recipients of its 2026 DREAMS Grant Program, awarding $50,000 each to projects addressing healthcare disparities and improving outreach to underserved members of the global Duchenne muscular dystrophy community. The initiative supports the company’s patient-focused reputation, although the grants are not expected to have a significant direct financial impact. Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program
• Neutral Sentiment: A report showing short interest of zero shares and a zero-day days-to-cover ratio appears internally inconsistent, including a reported “NaN” percentage change. As a result, it provides no meaningful indication of short-selling pressure or potential for a short squeeze.
• Negative Sentiment: Major shareholder Bioventures 2018 L.P. MPM disclosed additional sales of TRDA shares, including 28,837 shares on September 9 for approximately $206,000 and 192,500 shares on September 8 for about $1.43 million. The shareholder also sold shares in earlier September transactions, bringing the reported series to more than 433,000 shares. Although the fund still owns a substantial stake, repeated insider disposals can weigh on investor confidence and increase perceived supply. Entrada Therapeutics Major Shareholder Share Sale

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.